1 completed. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Cirrhosis, Cryptogenic: new trials by email Literature Review of Cirrhosis, Cryptogenic trials Research Report on Cirrhosis, Cryptogenic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency Sebelipase alfa (SBC-102) - Lysosomal Acid Lipase Deficiency, Wolman Disease | Phase 2 / Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 9 | 2011-05-04 | 2019-01-30 |
Chanarin-Dorfman Syndrome (1) · Cholesterol Ester Storage Disease (1) · Liver Diseases, Alcoholic (1) · Niemann-Pick Diseases (1) · Non-alcoholic Fatty Liver Disease (1) · Wolman Disease (1)
Alcohol-Induced Disorders (1) · Alcohol-Related Disorders (1) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Brain Diseases, Metabolic, Inborn (1) · Central Nervous System Diseases (1) · Chemically-Induced Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Fatty Liver (1) · Genetic Diseases, Inborn (1) · Hemic and Lymphatic Diseases (1) · Histiocytosis (1) · Histiocytosis, Non-Langerhans-Cell (1) · Infant, Newborn, Diseases (1)
Sebelipase alfa (1)
Alexion Pharmaceuticals, Inc. (1)
Egypt (1) · France (1) · Ireland (1) · United Kingdom (1) · United States (1)